Search Results - "ROSSI, J. F"

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial by Rossille, D, Gressier, M, Damotte, D, Maucort-Boulch, D, Pangault, C, Semana, G, Le Gouill, S, Haioun, C, Tarte, K, Lamy, T, Milpied, N, Fest, T

“…The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of adults with cancer has never been performed in a prospective patient…”
Get full text

A phase I II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer by Rossi, J-F, Négrier, S, James, N D, Kocak, I, Hawkins, R, Davis, H, Prabhakar, U, Qin, X, Mulders, P, Berns, B

“…Background: Serum interleukin (IL)-6 levels correlate with disease outcomes in renal cell carcinoma (RCC) patients. Siltuximab, a chimeric, murine-human mAb…”
Get full text

Insulin is a potent myeloma cell growth factor through insulin IGF-1 hybrid receptor activation by Sprynski, A C, Hose, D, Kassambara, A, Vincent, L, Jourdan, M, Rossi, J F, Goldschmidt, H, Klein, B

“…Insulin and insulin growth factor type 1 (IGF-1) and their receptors are closely related molecules, but both factors bind to the receptor of the other one with…”
Get full text

Atacicept in relapsed refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study by Rossi, J-F, Moreaux, J, Hose, D, Requirand, G, Rose, M, Rouillé, V, Nestorov, I, Mordenti, G, Goldschmidt, H, Ythier, A, Klein, B

“…Background: Advanced multiple myeloma (MM) and Waldenström's macroglobulinemia (WM) are incurable B-cell malignancies. This is the first full clinical report…”
Get full text

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma by MAHTOUK, K, CREMER, F. W, QUITTET, P, GOLDSCHMIDT, H, ROSSI, J.-F, HOSE, D, KLEIN, B, REME, T, JOURDAN, M, BAUDARD, M, MOREAUX, J, REQUIRAND, G, FIOL, G, DE VOS, J, MOOS, M

“…The epidermal growth factor (EGF)/EGF-receptor (ErbB1-4) family is involved in the biology of multiple myeloma (MM). In particular, ErbB-specific inhibitors…”
Get full text

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis by Seckinger, A, Meißner, T, Moreaux, J, Goldschmidt, H, Fuhler, G M, Benner, A, Hundemer, M, Rème, T, Shaughnessy, J D, Barlogie, B, Bertsch, U, Hillengass, J, Ho, A D, Pantesco, V, Jauch, A, De Vos, J, Rossi, J F, Möhler, T, Klein, B, Hose, D

“…Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by…”
Get full text

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma by Attal, Michel, Harousseau, Jean-Luc, Stoppa, Anne-Marie, Sotto, Jean-Jacques, Fuzibet, Jean-Gabriel, Rossi, Jean-François, Casassus, Philippe, Maisonneuve, Hervé, Facon, Thierry, Ifrah, Norbert, Payen, Catherine, Bataille, Régis

“…For the past 30 years, a combination of melphalan and prednisone has been the standard treatment for myeloma. Extensive trials of other drug combinations have…”
Get full text

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma by Morschhauser, F., Recher, C., Milpied, N., Gressin, R., Salles, G., Brice, P., Vey, N., Haioun, C., Colombat, P., Rossi, J.F., Deconinck, E., Lazreg, F., Bergougnoux, L., Delsol, G., Attal, M.

“…This study explored the efficacy and safety of rituximab as treatment of clinical or molecular residual disease after autologous stem-cell transplantation…”
Get full text

Ancestim (r-metHuSCF) plus filgrastim and or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience by Lapierre, V, Rossi, J-F, Heshmati, F, Azar, N, Vekhof, A, Makowski, C, Moreau, P, Caillot, D, Auperin, A, Chabannon, C

“…Ancestim (r-MetHuSCF) is available in France for compassionate use in patients who are candidates for high-dose chemotherapy and autologous transplantation,…”
Get full text

Extensive characterization of dendritic cells generated in serum-free conditions : regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro by TARTE, K, FIOL, G, ROSSI, J.-F, KLEIN, B

“…Dendritic cells (DC) play a key role in the initiation of primary immune response, and pilot clinical studies have demonstrated their ability to induce…”
Get full text

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial by Solal-Céligny, P, Lepage, E, Brousse, N, Tendler, C L, Brice, P, Haïoun, C, Gabarre, J, Pignon, B, Tertian, G, Bouabdallah, R, Rossi, J F, Doyen, C, Coiffier, B

“…To compare progression-free survival (PFS), overall survival (OS), and toxicity of a doxorubicin-containing regimen administered alone or in combination with…”
Get more information

Efficacy and Safety of Oral Fludarabine Phosphate in Previously Untreated Patients With Chronic Lymphocytic Leukemia by ROSSI, J.-F, DE BOECK, A. Van Hoof K, DECONINCK, E, MONTILLO, M, GUIBON, O, TOLLERFIELD, S. M, JOHNSON, S. A, BRON, D, FOUSSARD, C, LISTER, T. A, BERTHON, C, KRAMER, M. H. H, LITTLEWOOD, T. J, MARCUS, R. E

“…A prospective, multicenter, open-label, phase II clinical trial to assess oral fludarabine phosphate treatment in terms of safety, efficacy, and quality of…”
Get full text

Environmental Risk Factors for Non-Hodgkin's Lymphoma: A Population-Based Case-Control Study in Languedoc-Roussillon, France by Fabbro-Peray, Pascale, Daures, Jean-Pierre, Rossi, Jean-François

“…Objective: To investigate the occupational and environmental risk factors related to non-Hodgkin's lymphoma (NHL). Methods: A case-control study was performed…”
Get full text

Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma by Bataille, Rέgis, Barlogie, Bart, Lu, Zhao Yang, Rossi, Jean-François, Lavabre-Bertrand, Thierry, Beck, Thad, Wijdenes, John, Brochier, Jean, Klein, Bernard

“…In patients with advanced multiple myeloma (MM) there is an excess of production of interleukin-6 (IL-6) in vivo, and elevated serum levels are associated with…”
Get full text

Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors by GU, Z.-J, DE VOS, J, REBOUISSOU, C, JOURDAN, M, ZHANG, X.-G, ROSSI, J.-F, WIJDENES, J, KLEIN, B

“…We have previously reported obtaining two monoclonal antibodies (mAb) against the human gp130 interleukin-6 (IL-6) transducer which made possible the…”
Get full text

Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma by Blay, Jean‐Yves, Rossi, Jean‐François, Wijdenes, John, Menetrier‐Caux, Christine, Schemann, Stéphane, Négrier, Sylvie, Philip, Thierry, Favrot, Marie

“…We investigated the possible causative role of interleukin 6 (IL‐6) in the paraneoplastic inflammatory syndrome and in paraneoplastic cholestasis (Stauffer…”
Get full text

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma by HOSE, Dirk, REME, Thierry, HILLENGASS, Jens, BERTSCH, Uta, NEBEN, Kai, MÖHLER, Thomas, ROSSI, Jean Francois, JAUCH, Anna, KLEIN, Bernard, GOLDSCHMIDT, Hartmut, HIELSCHER, Thomas, MOREAUX, Jérôme, MESSNER, Tobias, SECKINGER, Anja, BENNER, Axel, SHAUGHNESSY, John D, BARLOGIE, Bart, YIMING ZHOU

“…Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g. tubulin…”
Get full text

CD200 is a new prognostic factor in multiple myeloma by Moreaux, Jerome, Hose, Dirk, Reme, Thierry, Jourdan, Eric, Hundemer, Michael, Legouffe, Eric, Moine, Philippe, Bourin, Philippe, Moos, Marion, Corre, Jill, Möhler, Thomas, De Vos, John, Rossi, Jean Francois, Goldschmidt, Hartmut, Klein, Bernard

“…Using Affymetrix microarrays, we identified the expression of the CD200 gene in multiple myeloma cells (MMCs) of 112 patients with newly diagnosed multiple…”
Get full text

Measurement of Whole Body Interleukin-6 (IL-6) Production: Prediction of the Efficacy of Anti-IL-6 Treatments by Lu, Zhao Yang, Brailly, Hervέ, Wijdenes, John, Bataille, Rέgis, Rossi, Jean-François, Klein, Bernard

“…A major limitation on the therapeutic use of cytokine antagonists is that the amount of cytokine to be neutralized in vivo is not presently known. We…”
Get full text

The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells by Jourdan, Michel, Ferlin, Martine, Legouffe, Eric, Horvathova, Mira, Liautard, Janny, Rossi, Jean FranÇois, Wijdenes, John, Brochier, Jean, Klein, Bernard

“…Syndecan‐1 is a cell membrane proteoglycan that binds extracellular matrix components and various growth factors. It is expressed only on malignant plasma…”
Get full text